<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO> WSJ870429-0182 </DOCNO><HL> Financing Business:Bio-Technology General Corp.</HL><DD> 04/29/87</DD><SO> WALL STREET JOURNAL (J)</SO><IN> BTGCBOND MARKET NEWS (BON) </IN><TEXT>   BIO-TECHNOLOGY GENERAL CORP. sold $20 million of 7 1/2% convertible senior subordinated notes priced at par and due 1997, said Drexel Burnham Lambert Inc., sole underwriter. The securities are convertible at a rate of $13.20 of notes for each common share. The New York-based biotechnology company will use proceeds to establish a research and development effort in the U.S., complete expansion of its production plant in Israel, to fund new research projects and for general purposes. </TEXT></DOC>